Since the discovery of a checkpoint blockade through the anti-PD-1- and anti-PD-L1-based immunotherapies and their successful application in cancers, including lung cancer, identifying which patients are most likely to respond remains a challenge [17]. The gene discussed is CD274; the disease is lung carcinoma.